Related references
Note: Only part of the references are listed.A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy
Hyung Shik Kim et al.
JOURNAL OF NANOBIOTECHNOLOGY (2022)
Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor
Hyung Shik Kim et al.
BIOACTIVE MATERIALS (2022)
Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
Parisa Shamshiripour et al.
FRONTIERS IN IMMUNOLOGY (2022)
Pharmaceutical application and development of fixed-dose combination: dosage form review
Dong-Wook Kim et al.
JOURNAL OF PHARMACEUTICAL INVESTIGATION (2021)
Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics
Joshua J. Rennick et al.
NATURE NANOTECHNOLOGY (2021)
Intestinal membrane transporter-mediated approaches to improve oral drug delivery
Rudra Pangeni et al.
JOURNAL OF PHARMACEUTICAL INVESTIGATION (2021)
Oral cavity: An open horizon for nanopharmaceuticals
Oanh Oanh Thi Nguyen et al.
JOURNAL OF PHARMACEUTICAL INVESTIGATION (2021)
The anti-cancer properties of heparin and its derivatives: a review and prospect
Sai-Nan Ma et al.
CELL ADHESION & MIGRATION (2020)
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients
David R. Anderson et al.
BLOOD ADVANCES (2019)
Dynamic Covalent Identification of an Efficient Heparin Ligand
Miriam Corredor et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Current Strategies for Brain Drug Delivery
Xiaowei Dong
THERANOSTICS (2018)
New Directions in Anti-Angiogenic Therapy for Glioblastoma
Nancy Wang et al.
NEUROTHERAPEUTICS (2017)
Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow
M. Guerra et al.
FLUIDS AND BARRIERS OF THE CNS (2017)
Antitumor and Antimetastasis Activities of Heparin-based Micelle Served As Both Carrier and Drug
Ling Mei et al.
ACS APPLIED MATERIALS & INTERFACES (2016)
Antiangiogenic actions of heparin derivatives for cancer therapy
Hae Hyun Hwang et al.
MACROMOLECULAR RESEARCH (2016)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2016)
Size Controlled Heparin Fragment-Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF165
Jooho Park et al.
BIOCONJUGATE CHEMISTRY (2015)
LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways
Seung Woo Chung et al.
BIOMATERIALS (2015)
In vitro and in vivo effect of human lactoferrin on glioblastoma growth
Antonietta Arcella et al.
JOURNAL OF NEUROSURGERY (2015)
The mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma
Mitsutoshi Nakada et al.
BRAIN TUMOR PATHOLOGY (2014)
Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy
Yunlei Zhang et al.
NUTRITION REVIEWS (2014)
Glioblastoma and Other Malignant Gliomas A Clinical Review
Antonio Omuro et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Mohammed Alquwaizani et al.
CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS (2013)
Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers
Laura M. Ensign et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides
Wenjing Zhao et al.
BIOSCIENCE REPORTS (2012)
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
Krystin Krauel et al.
BLOOD (2012)
Heparin-induced thrombocytopenia in the ICU: an overview
Yasser Sakr
CRITICAL CARE (2011)
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas
Marc C. Chamberlain
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Acetyl-11-Keto-β-Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis
Xiufeng Pang et al.
CANCER RESEARCH (2009)
Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor
Esak Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties
Melissa M. Kemp et al.
NANOTECHNOLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Antiangiogenic Activity of Orally Absorbable Heparin Derivative in Different Types of Cancer Cells
Dong Yun Lee et al.
PHARMACEUTICAL RESEARCH (2009)
Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence
Shaker A. Mousa et al.
THROMBOSIS AND HAEMOSTASIS (2009)
Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity
Bo-Jeong Pyun et al.
CANCER RESEARCH (2008)
Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin
Marina Marchetti et al.
THROMBOSIS RESEARCH (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate
Dong Yun Lee et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Mechanisms of heparin induced anti-cancer activity in experimental cancer models
T. M. H. Niers et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity
H Takahashi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells -: Comparison of the effects of heparin and modified heparins
S Ashikari- Hada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme
C Giannini et al.
NEURO-ONCOLOGY (2005)
Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling -: Role of divalent cations
S Ricard-Blum et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Share Paper
